Upregulation of CIP2A in estrogen depletion‐resistant breast cancer cells treated with low‐dose everolimus

Everolimus (EVE), an inhibitor of mammalian target of rapamycin, is an emerging second‐line therapeutic option for hormone therapy‐resistant breast cancers. However, some patients do not respond to EVE, whereas in others it exacerbates the disease. Cellular inhibitor of protein phosphatase 2A (CIP2A...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:FEBS Open Bio
Asıl Yazarlar: Nishio, Eiji, Hayashi, Takanori, Akaza, Mao, Hisatomi, Yukiko, Hikichi, Masahiro, Fujii, Takuma, Utsumi, Toshiaki, Harada, Nobuhiro, Shimono, Yohei
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2020
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7530388/
https://ncbi.nlm.nih.gov/pubmed/32810922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12956
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller